|
Oct 15
|
Pfizer invests in molecular glue; Jazz, MeiraGTx shares rise on drug data
|
|
Oct 14
|
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
|
|
Oct 14
|
Inventiva secures up to $380m for MASH treatment lanifibranor
|
|
Oct 14
|
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?
|
|
Oct 14
|
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
|
|
Oct 14
|
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
|
|
Jul 25
|
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
|
|
Jun 21
|
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024
|
|
Jun 21
|
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
|
|
Jan 10
|
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank
|
|
Dec 20
|
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program
|
|
Dec 4
|
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH
|
|
Sep 28
|
Inventiva reports its 2023 first-half financial results and provides a corporate update
|